Montecito Bank & Trust Invests $3.23 Million in Johnson & Johnson $JNJ

Montecito Bank & Trust bought a new stake in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 17,427 shares of the company’s stock, valued at approximately $3,231,000.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $4,877,174,000. Laurel Wealth Advisors LLC grew its position in Johnson & Johnson by 15,040.6% in the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after purchasing an additional 7,371,687 shares in the last quarter. Vanguard Group Inc. increased its stake in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $401,420,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.0%

Shares of Johnson & Johnson stock opened at $208.23 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The business has a fifty day simple moving average of $197.78 and a two-hundred day simple moving average of $178.67. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The company has a market capitalization of $501.68 billion, a price-to-earnings ratio of 20.10, a P/E/G ratio of 2.28 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. UBS Group upped their target price on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Guggenheim raised their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Finally, HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $210.25.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.